Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.87 |
| ▸ | TSHR | P16473 | 5/20 | 0.87 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.87 |
| ▸ | NPC1 | O15118 | 2/20 | 0.87 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.87 |
| ▸ | RAB9A | P51151 | 2/20 | 0.87 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.87 |
| ▸ | RELA | Q04206 | 2/20 | 0.87 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.87 |
| ▸ | LMNA | P02545 | 6/20 | 0.73 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10973042 | 0.87 | ALDH1A1 (0.71) | ALDH1A1TSHRL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL10970208 | 0.87 | ALDH1A1 (0.71) | ALDH1A1TSHRL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL7303919 | 0.84 | ALDH1A1 (0.66) | ALDH1A1TSHRL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL7301329 | 0.84 | ALDH1A1 (0.66) | ALDH1A1TSHRL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL16116944 | 0.81 | ALDH1A1 (0.72) | ALDH1A1TSHRL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL10972734 | 0.81 | ALDH1A1 (0.63) | ALDH1A1TSHRL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL16526226 | 0.80 | ALDH1A1 (0.70) | ALDH1A1TSHRL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL18686921 | 0.80 | ALDH1A1 (0.72) | ALDH1A1TSHRL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL6510534 | 0.79 | ALDH1A1 (0.63) | ALDH1A1TSHRL3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL24305911 | 0.79 | ALDH1A1 (0.68) | ALDH1A1TSHRL3MBTL1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099419-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-03-27 | — | — | US | disclosed |
| US-12201603-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20230190698-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-11617733-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-04-04 | — | — | US | disclosed |
| US-20210169842-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-10 | — | — | US | disclosed |
| US-10940134-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2021-03-09 | — | — | US | disclosed |
| US-20200093781-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-03-26 | — | — | US | disclosed |
| US-20190111019-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-04-18 | — | — | US | disclosed |
| US-10201520-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-02-12 | — | — | US | disclosed |
| US-20180116995-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-03 | — | — | US | disclosed |
| EP-2653468-B1 | Bicyclic Compound and Use Thereof for Medical Purposes | ONO PHARMACEUTICAL CO (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-20150112079-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-04-23 | — | — | US | disclosed |
| US-8962868-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-02-24 | — | — | US | disclosed |
| EP-2460801-B1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO (JP) | 2014-06-25 | — | — | EP | disclosed |
| CN-102498105-B | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICAL CO | 2014-04-02 | — | — | CN | disclosed |
| US-20140073676-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-13 | — | — | US | disclosed |
| US-8614340-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICALS CO., LTD. (JP) | 2013-12-24 | — | — | US | disclosed |
| EP-2653468-A1 | Bicyclic Compound and Use Thereof for Medical Purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-23 | — | — | EP | disclosed |
| EP-2460801-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO Pharmaceutical Co., Ltd. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120122964-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190698-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | ALDH1A1 716/4885TSHR 3997/4885L3MBTL1 4263/4885 |
| US-20250099419-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | ALDH1A1 716/4885TSHR 3997/4885L3MBTL1 4263/4885 |
| US-20180116995-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | ALDH1A1 716/4885TSHR 3997/4885L3MBTL1 4263/4885 |
| US-20200093781-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | ALDH1A1 716/4885TSHR 3997/4885L3MBTL1 4263/4885 |
| US-11617733-B2 | Bicyclic compound and use thereof for medical purposes | CYP4A11, PDE3A, GUCY1B1 | ALDH1A1 716/4885TSHR 3997/4885L3MBTL1 4263/4885 |
| US-10201520-B2 | Bicyclic compound and use thereof for medical purposes | CYP4A11, PDE3A, GUCY1B1 | ALDH1A1 716/4885TSHR 3997/4885L3MBTL1 4263/4885 |
| US-20190111019-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | ALDH1A1 716/4885TSHR 3997/4885L3MBTL1 4263/4885 |
| US-10940134-B2 | Bicyclic compound and use thereof for medical purposes | CYP4A11, PDE3A, GUCY1B1 | ALDH1A1 716/4885TSHR 3997/4885L3MBTL1 4263/4885 |
| US-20210169842-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | ALDH1A1 716/4885TSHR 3997/4885L3MBTL1 4263/4885 |
| US-12201603-B2 | Bicyclic compound and use thereof for medical purposes | CYP4A11, PDE3A, GUCY1B1 | ALDH1A1 716/4885TSHR 3997/4885L3MBTL1 4263/4885 |
| US-20150112079-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | ALDH1A1 716/4885TSHR 3997/4885L3MBTL1 4263/4885 |
| US-20140073676-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | ALDH1A1 716/4885TSHR 3997/4885L3MBTL1 4263/4885 |
| US-20120122964-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | CYP4A11, PDE3A, GUCY1B1 | ALDH1A1 716/4885TSHR 3997/4885L3MBTL1 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.